GlassScriptPhysician profile
Tommy Wood
NPI 1710008651
$4,270.65
in general payments reported to CMS, 2019-2025
33 companies · $624 in 2025
The $624 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,250 · 2021: $12.19 · 2022: $35.93 · 2023: $1,326 · 2024: $1,023 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,972.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $894.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $690.10 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Mylan Specialty L.P. | $514.74 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.32 | 2019-2023 | Ofev |
| Grifols USA, LLC | $225.95 | 2019-2025 | Prolastin-C Liquid |
| Insmed, INC. | $220.61 | 2019-2024 | Arikayce |
| Genzyme Corporation | $209.62 | 2023-2024 | |
| Genentech USA, INC. | $179.20 | 2019 | |
| Inspire Medical Systems, INC. | $177.12 | 2024-2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $91.27 | 2024-2025 | Glassia |
| Harmony Biosciences LLC | $88.26 | 2023-2025 | Wakix |
| Viatris Specialty LLC | $83.87 | 2025 | Yupelri |
| United Therapeutics Corporation | $73.17 | 2023-2024 | Tyvaso |
| Verona Pharma, INC. | $72.20 | 2025 | Ohtuvayre |
| Philips North America LLC | $50.07 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $44.08 | 2023-2024 | Tezspire |
| Medtronic, INC. | $44.00 | 2023 | Illumisite |
| 3b Medical, INC. | $40.62 | 2025 | Luna |
| Jazz Pharmaceuticals INC. | $36.81 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $32.02 | 2023 | Acthar |
| Mallinckrodt Enterprises LLC | $31.94 | 2019 | |
| Sunovion Pharmaceuticals INC. | $28.34 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.93 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.96 | 2019 | |
| Boston Scientific Corporation | $21.87 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.41 | 2019 | |
| Baxter Healthcare | $17.96 | 2024 | Hillrom - Monarch Airway Clearance System |
| Fisher & Paykel Healthcare INC | $17.44 | 2024 | Fisher & Paykel Healthcare |
| Arbor Pharmaceuticals, INC. | $16.90 | 2019 | |
| Advanced Respiratory, INC | $16.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.37 | 2019 | |
| Shire North American Group INC | $13.25 | 2019 | |
| Phadia US INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tommy Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.